AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has picked up a new approval in Europe, as a monotherapy in gast 19 December 2022
UK-based STORM Therapeutics, a clinical biotech discovering and developing small molecule therapies targeting RNA modifying enzymes for oncology and other disea 14 December 2022
Privately-held Danish firm LEO Pharma has announced that both the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHR 28 November 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.